1. Home
  2. MDXH vs RFL Comparison

MDXH vs RFL Comparison

Compare MDXH & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDXH
  • RFL
  • Stock Information
  • Founded
  • MDXH 2003
  • RFL 2017
  • Country
  • MDXH Belgium
  • RFL United States
  • Employees
  • MDXH N/A
  • RFL N/A
  • Industry
  • MDXH
  • RFL Real Estate
  • Sector
  • MDXH
  • RFL Finance
  • Exchange
  • MDXH Nasdaq
  • RFL Nasdaq
  • Market Cap
  • MDXH 84.6M
  • RFL 67.7M
  • IPO Year
  • MDXH 2021
  • RFL N/A
  • Fundamental
  • Price
  • MDXH $2.44
  • RFL $2.05
  • Analyst Decision
  • MDXH Buy
  • RFL
  • Analyst Count
  • MDXH 1
  • RFL 0
  • Target Price
  • MDXH $6.00
  • RFL N/A
  • AVG Volume (30 Days)
  • MDXH 54.9K
  • RFL 238.1K
  • Earning Date
  • MDXH 08-20-2025
  • RFL 06-11-2025
  • Dividend Yield
  • MDXH N/A
  • RFL N/A
  • EPS Growth
  • MDXH N/A
  • RFL N/A
  • EPS
  • MDXH N/A
  • RFL N/A
  • Revenue
  • MDXH $94,507,000.00
  • RFL $732,000.00
  • Revenue This Year
  • MDXH $23.51
  • RFL N/A
  • Revenue Next Year
  • MDXH $17.68
  • RFL N/A
  • P/E Ratio
  • MDXH N/A
  • RFL N/A
  • Revenue Growth
  • MDXH 25.46
  • RFL 35.56
  • 52 Week Low
  • MDXH $1.35
  • RFL $1.28
  • 52 Week High
  • MDXH $3.50
  • RFL $3.19
  • Technical
  • Relative Strength Index (RSI)
  • MDXH 64.50
  • RFL 59.74
  • Support Level
  • MDXH $2.17
  • RFL $2.09
  • Resistance Level
  • MDXH $2.35
  • RFL $2.32
  • Average True Range (ATR)
  • MDXH 0.07
  • RFL 0.19
  • MACD
  • MDXH 0.01
  • RFL 0.03
  • Stochastic Oscillator
  • MDXH 96.90
  • RFL 57.23

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

Share on Social Networks: